WEST TISBURY, Massachusetts

Radikal Therapeutics today announced that the Company has been joined by Dr. Kanneganti Murthy, who will assume the position of Senior Director of Biology. Dr. Murthy is an experienced molecular biologist and biochemist, with more than 25 years experience in academia and the pharmaceutical industry. Among his scientific accomplishments, He has previously reported in Nature the discovery, purification, characterization, cloning, and expression of novel RNA binding proteins from complex mixtures of cellular extracts. In his previous position as Director of Biology at Inotek Pharmaceuticals Corporation, Dr. Murthy produced and patented novel broad-spectrum anti-flagellin human monoclonal antibodies, and led the Company’s poly(ADP-ribose) polymerase biology program, culminating in a multi-hundred million dollar strategic partnership with Genentech. In addition, Dr. Murthy led Inotek’s pharmacology and biology programs in Adenosine 1, 2a, and 3 receptor technology, built its purinergic small molecule program in inosine biology, and supervised the discovery work that formed the basis of its nitric oxide synthase inhibitor, xanthine oxidase inhibitor, and peroxynitrite decomposition catalyst programs. His research efforts formed the basis for more than ten clinical programs at Inotek Pharmaceuticals.

About Radikal Therapeutics (RTX)

RTX is a multi-national biotechnology firm focused on the discovery and development of transformative pharmaceuticals. With a deep pipeline of therapeutics created in-house, and a paradigm-disruptive discovery engine, the Company is positioned to remain at the forefront of drug discovery. RTX’s team of chemists, biologists, immunologists, and drug development professionals has worked together for more than two decades and has built a reputation for leadership in basic science and drug development. The Company is developing best-in-class therapeutics in a range of clinical areas, including inflammation, ischemia-reperfusion injury, and auto-immunity. The product platforms include small and large molecule pharmaceuticals that therapeutically restore free radical equilibrium, redirect aberrant signaling pathways in inflammation, manipulate mitochondrial cell death pathways, modulate DNA repair, restore microcirculatory perfusion, and induce specific immunotolerance. Although varied in their structural targets and directed at diverse clinical needs, the Company’s technologies share a unified concept of correcting pathophysiology by endowing agents with multi-functional capacity. This approach yields biological synergies that far outstrip the potency of traditional single-target agents.

Via its sister firm Luria Scientific Industries (LSI), RTX makes available its deep and unique experience in pre-clinical and clinical development for the benefit of the biotech and pharmaceutical industry.


Andrew L. Salzman, M.D.



1-866-925-2871 x.709